logo
LIBOGENE is in the business of cancer molecular diagnosis. The company has established an internationally certified CAP laboratory, and is building a tumor mutant gene databank. LIBOGENE has successfully developed many targeted cancer treatment testing panels and identified novel indigenous tumor resistant gene mutations which can be used as important diagnostic biomarkers.
If you have any questions about our products and services, please input the following details, we will contact you as soon as possible to answer your questions.

繁中  |  简中  |  ENG

Comprehensive cancer gene detection panel

LIBOGENE / Comprehensive cancer gene detection panel

Comprehensive cancer gene detection panel

The comprehensive cancer gene detection panel detects 30 genes and 280 mutation sites, including specific gene mutations that code for the targets for targeted therapies and tumor resistant gene mutations which can be used as important diagnostic biomarkers. We aim to help physicians identify the right drugs so that treatment effect could be maximized while reducing unwanted treatment-induced side effects.

Gene target

Detection of gene EGFR、KRAS、BRAF、PIK3CA、PTEN、AKT1、MLH1、FLT3、DDR2、RET、MEK1、ALK、SMAD4、NRAS、HER2、HRAS、TSC1、CRLF2、JAK2、SMO、DNMT3A、IDH1、IDH2、KIT、ABL1、CTNNB1、GNAQ、GNA11、ESR1、PDGFRA
Detection of mutations point 280

Description

DNA Demand ≥3ng
Inspection type DNA Purification、formalin-fixed, paraffin-embedded tissues
Sequencing depth >1500x
Report Gene mutation sites and Medication advice